Case series of liver failure associated with rosiglitazone and pioglitazone

Purpose The thiazolidinedione drugs rosiglitazone and pioglitazone are not widely known to be hepatotoxic. We evaluated the FDA Adverse Event Reporting System (AERS) to determine the number of reported cases of liver failure associated with rosiglitazone and pioglitazone between 1997 and 2006, and d...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacoepidemiology and drug safety 2009-12, Vol.18 (12), p.1238-1243
Hauptverfasser:	Floyd, James S., Barbehenn, Elizabeth, Lurie, Peter, Wolfe, Sidney M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse Drug Reaction Reporting Systems adverse event reporting AERS Aged Chemical and Drug Induced Liver Injury - etiology Data processing Databases, Factual Diabetes Mellitus, Type 2 - drug therapy drug-induced liver injury Drugs Etiology FDA Female Hepatic encephalopathy hepatotoxicity Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Immunosuppressive agents Injuries Liver Liver diseases liver failure Liver Failure - chemically induced Liver transplantation Male Middle Aged Mortality pioglitazone Risk Factors rosiglitazone Side effects thiazolidinediones Thiazolidinediones - adverse effects Thiazolidinediones - therapeutic use Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!